Market Cap | 553.93M | P/E | 38.36 | EPS this Y | -125.00% | Ern Qtrly Grth | - |
Income | 4.95M | Forward P/E | 26.38 | EPS next Y | 700.00% | 50D Avg Chg | 10.00% |
Sales | 433.14M | PEG | -103.32 | EPS past 5Y | - | 200D Avg Chg | 46.00% |
Dividend | N/A | Price/Book | 2.10 | EPS next 5Y | 2.41% | 52W High Chg | -35.00% |
Recommedations | 2.00 | Quick Ratio | 2.31 | Shares Outstanding | 131.96M | 52W Low Chg | 135.00% |
Insider Own | 33.27% | ROA | 2.24% | Shares Float | 62.16M | Beta | 1.57 |
Inst Own | 44.86% | ROE | 1.82% | Shares Shorted/Prior | 8.32M/8.01M | Price | 4.22 |
Gross Margin | 75.42% | Profit Margin | 1.14% | Avg. Volume | 1,081,440 | Target Price | 4.83 |
Oper. Margin | 0.65% | Earnings Date | May 8 | Volume | 746,556 | Change | -1.63% |
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.
Cantor Fitzgerald | Overweight | Mar 1, 24 |
Cantor Fitzgerald | Overweight | Feb 7, 24 |
BTIG | Buy | Dec 27, 23 |
Morgan Stanley | Equal-Weight | Nov 14, 23 |
Morgan Stanley | Equal-Weight | Aug 11, 23 |
BTIG | Buy | Aug 10, 23 |
Morgan Stanley | Equal-Weight | Jun 15, 23 |
BTIG | Buy | May 24, 23 |
BTIG | Neutral | Nov 10, 22 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
ERANI ALBERT | 10% Owner 10% Owner | Jan 09 | Sell | 4.32 | 215,893 | 932,658 | 59,007,134 | 01/11/24 |
ERANI ALBERT | 10% Owner 10% Owner | Apr 12 | Sell | 2.0709 | 25,000 | 51,772 | 59,223,027 | 04/14/23 |
Grow Brian | Chief Commercial Off.. Chief Commercial Officer | Aug 20 | Option | 1.46 | 805 | 1,175 | 87,744 | 08/24/22 |
Leibowitz Arthur S | Director Director | Aug 12 | Buy | 4.755 | 3,000 | 14,265 | 70,854 | 08/15/22 |
Driscoll Michael Joseph | Director Director | Aug 12 | Buy | 4.80 | 5,000 | 24,000 | 25,547 | 08/15/22 |
Gillheeney Gary S. | President and CEO President and CEO | Jun 30 | Option | 0.99 | 505,050 | 500,000 | 903,292 | 07/01/22 |
ERANI ALBERT | 10% Owner 10% Owner | Jun 09 | Sell | 5.1 | 30,000 | 153,000 | 59,248,027 | 06/13/22 |
ERANI ALBERT | 10% Owner 10% Owner | Jun 06 | Sell | 5.43 | 170,000 | 923,100 | 59,278,027 | 06/08/22 |
Gillheeney Gary S. | President and CEO President and CEO | May 26 | Option | 0.99 | 226,804 | 224,536 | 507,482 | 05/31/22 |
Gillheeney Gary S. | President and CEO President and CEO | May 26 | Sell | 5.77 | 226,804 | 1,308,659 | 398,242 | 05/31/22 |
Gillheeney Gary S. | President and CEO President and CEO | May 23 | Option | 0.99 | 197,336 | 195,363 | 482,916 | 05/25/22 |
Gillheeney Gary S. | President and CEO President and CEO | May 23 | Sell | 5.73 | 197,336 | 1,130,735 | 398,242 | 05/25/22 |
Gillheeney Gary S. | President and CEO President and CEO | May 18 | Option | 0.99 | 263,689 | 261,052 | 456,896 | 05/20/22 |
Gillheeney Gary S. | President and CEO President and CEO | May 18 | Sell | 5.76 | 263,689 | 1,518,849 | 398,242 | 05/20/22 |
KATZ MICHAEL W | 10% Owner 10% Owner | May 16 | Buy | 6.03 | 10,000 | 60,300 | 70,382 | 05/18/22 |
Gillheeney Gary S. | President and CEO President and CEO | May 13 | Option | 0.99 | 314,837 | 311,689 | 496,320 | 05/17/22 |
Gillheeney Gary S. | President and CEO President and CEO | May 13 | Sell | 6.02 | 314,837 | 1,895,319 | 398,242 | 05/17/22 |
Montecalvo Antonio S. | Vice President, Heal.. Vice President, Health Policy | Mar 09 | Option | 3.46 | 68,504 | 237,024 | 141,725 | 03/11/22 |
Montecalvo Antonio S. | Vice President, Heal.. Vice President, Health Policy | Mar 09 | Sell | 8.46 | 107,436 | 908,909 | 44,289 | 03/11/22 |
KATZ MICHAEL W | 10% Owner 10% Owner | Dec 02 | Buy | 9.55 | 2,600 | 24,830 | 59,882 | 12/06/21 |
KATZ MICHAEL W | 10% Owner 10% Owner | Nov 26 | Buy | 9.79 | 2,000 | 19,580 | 56,282 | 11/30/21 |